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. Labora tories for the quality control of pharmaceutical products bear a major responsibility for the re sults obtained and conclusions made on their basis on the con formity of the tested samples with the requirements o f the specifica tions, because the success of the treatment of patients or even their life depends on the results of such studies [2] . On the other hand, the results o f the medicines quality control determine for the manu facturer and distributor the pos sibility of implementing a series of medicines, and the error here may be due to significant direct and indirect financial losses, the loss o f the image of a reliable supplier or even revocation o f the license for the medicines production [3] .
Reliability, correctness and accuracy of the obtained analyt ical results depend on many in terconnected factors: laboratory managem ent, document circu lation, competence o f specialists, correctness o f application and relevance of analytical methods, materials and reagents, m etro logical characteristics and state o f service o f measuring instru ments (devices, equipment), stor age conditions and preparation o f analytical samples, hardware and software etc. [4] .
State laboratories for qual ity control of medicines should documented guarantee the cor rectness of the obtained results, prove their competence not only to their customers, but also to regulatory bodies [5] . Today is recognized that the status of an accredited laboratory does not provide such a guarantee: the necessary condition for the proof o f the tests results is the introduction and constant maintenance o f an effective quality assurance system in the working state [6] .
For the unification and standardization o f the requirements for the operation of national laboratories for the quality control o f medicines at the international level, the World Health Orga nization (WHO) has developed official guidelines "Good prac tices for pharmaceutical quality control laboratories" [1] , which is based on requirements of the standard ISO/IEC 17025 [2] .
These recommendations, with some minor changes, are applied as the basis o f their national rules by many countries o f the world.
The ISO/IEC 17025 standard has become an international standard for the development of laboratory QMS. The current version of ISO/IEC 17025 was published in 2005. Changes in market conditions, developments in the field of information tech nology, changes to the ISO 9001 standard, have led to the need for changes of ISO/IEC 17025, the revision of which began in 2015 and conducted jointly with the International Accreditation Com munity (ILAC) and the South Af rican Bureau of Standards (SABS). At present, the revision of the standard has reached the stage of the "Final Draft International Standard" (FDIS) [7] , which is the last stage until the publication of the international standard.
According to ISO / IEC FDIS 17025:2016 (E) [7] , paragraph 8, "Management System", laborato ries should harm onize their work in accordance with the principles of ISO 9001 [8] . In this regard, the main changes in the standard concern:
-use o f the process approach provided by the updated stan dards ISO 9001 [8] , ISO 15189 [9] and ISO / IEC 17021-1 [10] ; -application o f computerized systems, electronic records, elec tronic results preparation proce dures and reports [11] ; -im plem ent risk -orien ted thinking (paragraph 8.5) in ac cordance with the provisions of ISO 9001:2015 [8] .
Taking into account the up com ing innovations in ISO / IEC 17025 [8] and the lack of expe rience with the staff of dom es tic pharm aceutical laboratories regarding the implementation of effective QMS in accordance with current requirements, the issue of developing a methodol ogy for laboratories QMS con structing remains open and re quires research. Abstract: The article reviews the regulatory framework in the field of regulating the activities o f laboratories for qual ity control of medicines at the world and national levels. Taking into account the harmonization of the new version of ISO/IEC 17025 "General requirements for the competence of testing and calibration laboratories" and ISO 9001:2015 "Qual ity management systems. Requirements", the necessity of wide implementation of the process approach and implementation of risk-oriented thinking in the activities of laboratories has been substantiated. The general approaches to implementa tion of quality management systems (QMS) in the activity of testing pharmaceutical laboratories are offered. In particular, a typical list of QMS processes of the laboratory for quality con trol of medicines has been developed, and the division of such processes into three groups is proposed: management process es, resource provision processes, main (analytical testing) pro cesses. It is substantiated that these groups of processes should be described in the Quality Manual with a mandatory graphic representation of the QMS process model structure with a de scription of the processes interaction conditions. The use of the PDCA Cycle within each of the processes has been proven to promote systematic measurement, analysis o f activities and the development of effective corrective and preventive actions (CAPA). The formation of effective QMS in state and private laboratories for quality control of medi cines will help to reduce the number and significance of in consistencies and errors in analytical work, and to provide proper guarantees for obtaining reliable results, to increase the awareness of staff in quality management methods and continuous improvement. Keywords: quality management system, laboratory, process approach, standards, ISO 9001, ISO 17025, PDCA Cycle, medicines, quality control.
PHARMACOLOGY, TOXICOLOGY AND PHARMACEUTICAL SCIENCE QMS, as well as official statistical data and provisions o f nor mative documents concerning the above-mentioned questions. At the paper used: historical, logical and system-analytical methods (to find out the level of development o f the problem in foreign and domestic literature); the method of structur al-logical modeling (to describe the conceptual approaches to the formation and development o f QMS); the method of com parative analysis (used to generalize existing approaches to the formation of QMS in accordance with international standards).
Results
The analysis o f the QMS implementation in the pharm a ceutical laboratories showed the sim ilarity of the approaches used, despite differences in the number o f personnel, assort ment o f m ethods o f analysis, m aterial resources, infrastruc ture [5] . The sim ilarity o f approaches involves a sim ilar classi fication of processes and the structure o f the QMS, as well as a sim ilar set of documents and form s o f records. This is due to a fundam entally sim ilar type of laboratory and the sim ilarity o f the main activities. The organization o f laboratories, espe cially state-owned, non-commercial laboratories, has distinct peculiarities that require a serious adaptation o f approaches to the creation of QMS.
Firstly, to assess the degree o f accuracy and reliability of the main result o f the work of laboratories is more difficult than to evaluate the results o f activities o f m anufacturing enterprises or distributors. For this purpose, there are rounds of professional testing program s o f laboratories, internal "cross-checks", when one and the same sample is analyzed by several analysts to re veal discrepancies in results and their causes [3, 9] .
Secondly, the lack o f a competitive environment for state laboratories leads to a loss of incentive to improve the quality o f services provided. This problem has recently been aggravated by modest government funding and the recent significant cuts in personnel.
To solve the first problem, an effective QMS is needed, it can minim ize or even eliminate risk factors for the quality of test results. Process-oriented management provides for a clear allocation o f responsibilities, the regulation o f all types o f ac tivities that affect the final result, as well as the establishment o f indicators and criteria for assessing the effectiveness of all processes for the possibility of their continuous improvement.
The solution o f the second problem is impossible without the actions of the central governing body, which must develop and implement not only a system of continuous monitoring and control of the activities o f laboratories, but also take measures to motivate employees.
Having analyzed the requirements o f the standard ISO 9001:2015 [8] , the general procedure for developing QMS can formulated as follows: a) to determine the processes necessary for the QMS, as well as their application throughout the organization; b) to determine the sequence and interaction o f these QMS processes; c) to define the criteria and methods necessary to ensure the effectiveness of the operation o f these processes and their management; d) to ensure the availability of the resources and inform a tion necessary to support the operation and monitoring of these processes; e) to carry out monitoring, measurement and analysis of processes; f) to take measures necessary to achieve the planned results and continuous improvement of the QMS processes.
Implementation of the process-oriented approach to the organization o f laboratory activities and the creation o f a pro cess model o f the QMS lies in the area of responsibility of the management o f the laboratory. At this stage, it is necessary to define the processes of the QMS, to appoint their managers, to develop algorithms for the implementation o f the processes and the conditions of interaction between them, as well as to define the inputs, outputs, resources, necessary management actions and means of measurement, monitoring and analysis of all processes o f QMS.
An approximate list of QMS processes developed for a lab oratory with a small state and lim ited resources is proposed:
1. Processes o f m anagem ent activity (m anagem ent p ro cesses):
-management of QMS (quality policy development, stra tegic and operational planning, responsibility and authority allocation, information exchange, systematic monitoring of all processes, critical analysis of QMS by management, actions in case of discrepancies, development and implementation o f cor rective and preventive actions with the purpose of continuous improvement of activity);
-implementation of internal audits of the QMS. -actions in the case o f receiving abnormal (unusual, unex pected) results, or outcomes beyond the specifications; -registration and storage o f arbitration samples.
The following groups o f processes should be described in the Quality Manual, where it is also necessary to bring the graphic structure o f the QMS process model and specify the conditions for the interaction o f processes (their inputs and out puts), their monitoring, analysis, distribution o f responsibility for each process (for example, using the "responsibility m atrix"). Also needs to refer to lower level documents, such as Standard Operation Procedures (SOP) and instructions o f various kinds (e. g. operating instructions for analytical equipment use, etc.).
The systematic measurement, analysis and adoption of correc tive and preventive actions (implementation o f the Deming-Shewhart Cycle, PDCA) within each individual process for small laboratories are not rational because they take a considerable amount of time. It believed that it is better to implement the PDCA Cycle in each o f these process group data. The condi tions for implementing these actions should also described in the Quality Manual. The monitoring and analysis procedures should documented in the relevant SOP.
By determining the required amount of document flow, the depth and accuracy o f SOPs that describe a particular process, a registered quality person may use a methodology for assess ing the risk by the quality of the test result. Using the internal classification o f the criticality of the QMS processes, it is noted that some o f the m ost critical processes require more detailed documentation and more extensive training of staff. For exam ple, the FMEA method or other common methods and tools can used to establish a measurable characteristic of the criticality risk of each process.
These relatively new types of activities for laboratories such as internal audits, corrective and preventive actions, critical analysis by management, monitoring and analysis o f processes, etc., need to be regulated in the documents of the laboratory QMS, applying the requirements of the relevant sections o f the ISO 9001 standard. Recommendations for the implementation of internal audits are described in the standard ISO 19011:2011 [12] . In addition, it makes sense to use other ISO standards, such as 10012 (for metrological support) [13] , 10013 (for QMS docu mentation) [14] , 10015 (for personnel training) [15] , and others.
D iscu ssio n
The analysis of the literature has shown that the construc tion of QMS o f quality control laboratories is considered as recommendations for the development of regulatory documents of the QMS [16] and corrective and preventive actions [17] without describing the QMS processes and justifying the ratio nality o f using the PDCA Cycle. The QMS of the laboratory, the approaches to formation of which are described above, will be a certain hierarchical system o f those processes that influence the results of tests, with clear regulation and distribution of respon sibility, mechanisms of self-evaluation and self-regulation. The construction of effective QMS in state laboratories for quality control of medicines will help to reduce the number and signif icance o f inconsistencies and errors, to increase the probability of reliable results, to increase the awareness of staff. These m ea sures should definitely be considered progressive both for the national quality control system for medicines and for the entire domestic pharmaceutical market.
